Navigation Links
A hallmark for the development of testicular tumors found in the aberrant regulation of small non-coding RNA
Date:11/21/2013

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, Spain, have studied the role of a peculiar class of small non-coding RNAs that are mainly expressed in the human male germline. Whereas messenger RNAs transmit the genetic information required for protein synthesis, non-coding RNAs are functional molecules that are never translated into proteins and have important roles in diverse cellular processes. In human spermatozoa, these tiny RNAs are epigenetically regulated (by changes in the genome that do not alter the DNA sequence, such as DNA methylation) and play a critical role in male germline development. Importantly, these RNAs have also been detected in human cancer cells.

In a work published in the January 2014 issue of Epigenetics, which is entirely devoted to "Non-coding RNAs in Epigenetic Regulation," the researchers asked if in their natural functional context (the normal human testis) these small RNAs undergo aberrant epigenetic regulation, compromising their function and contributing to the transformation of cells into testicular tumor cells. The reported data suggest that epigenetic disruption of an entire small non-coding RNA pathway in human testis is indeed a hallmark for the development of testicular tumors.


'/>"/>

Contact: Andrew Thompson
andrew@landesbioscience.com
Landes Bioscience
Source:Eurekalert

Page: 1

Related biology news :

1. Artificial womb unlocks secrets of early embryo development
2. REST is crucial for the timing of brain development
3. Embryonic development protein active in cancer growth
4. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
5. Stomata development in plants unraveled -- a valuable discovery for environmental research
6. Promising developments in early diagnosis and treatment of mesothelioma
7. Europe meets to discuss progress in energy research and development
8. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
9. New genes contributing to autism and related neurodevelopmental disorders uncovered
10. Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinsons drug development tools
11. Navigating the IP Minefield of Human Embryonic Stem Cell Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... Systems, Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & ... intelligence provider visiongain offers comprehensive analysis of ... that this market will generate revenues of $17.98 billion ... Systems acquired DVTEL Inc, a leader in software and ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... , December 5, 2016 ... "Cell Expansion Market, by Products (Consumable, Instruments, Automated ... (Regenerative Medicine and Stem Cell Research, Cancer, and ... Institutes, Cell Banks) - Global Revenue, Trends, Growth, ... Scalar Market Research, the global cell expansion market ...
(Date:12/5/2016)... 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the ... and Safety Monitoring Board (DSMB) for the Company,s ... (CVD) patients has completed a second planned safety ... as planned without any modifications. The DSMB reviewed ... or efficacy concerns were identified. The DSMB will ...
(Date:12/5/2016)... Dec. 5, 2016  Eisai Inc. announced today ... study of rufinamide, which were presented at the ... (AES) held from December 2-6 in ... safety, tolerability and cognitive data showed that patients ... safety and tolerability profiles, cognitive development and behavior, ...
(Date:12/5/2016)... 5, 2016 The U.S. Biotechnology ... $108 billion of revenue and some $890 billion of ... on global biopharmaceuticals, and this figure is expected to ... lined up these four equities for assessment: Northwest Biotherapeutics ... (NASDAQ: ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
Breaking Biology Technology: